The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1008
August 29, 1997
View Complete Issue         Table of Contents 2019 
Samarium-153 Lexidronam for Painful Bone Metastases
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Samarium-153 Lexidronam for Painful Bone Metastases
August 29, 1997 (Issue: 1008)
Samarium-153 lexidronam (Quadramet - Dupont Pharma) has been approved by the FDA for relief of pain in patients with osteoblastic bone metastases. Strontium-89 (Metastron) has been available for several years for this indication (Medical Letter, ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Samarium-153 Lexidronam for Painful Bone Metastases
Article code: 1008b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.